Disc Medicine, Inc. $IRON Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Disc Medicine by 138.7% to 27,301 shares (about $2.17M), and institutional investors now own 83.7% of the company.
• Analysts maintain a Moderate Buy consensus (10 Buys, 1 Hold, 1 Sell) with a consensus target of $104.80, though several firms recently cut their price targets.
• Insiders have been net sellers, including two sales on Feb. 17, totaling 59,410 shares sold in the last 90 days (≈$3.84M); insiders now own 3.64% of the stock.

Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 138.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 27,301 shares of the company's stock after acquiring an additional 15,863 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.07% of Disc Medicine worth $2,168,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in IRON. Aster Capital Management DIFC Ltd acquired a new stake in shares of Disc Medicine during the 3rd quarter worth about $38,000. KBC Group NV acquired a new stake in shares of Disc Medicine during the 4th quarter worth about $80,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Disc Medicine by 36.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company's stock worth $146,000 after acquiring an additional 490 shares in the last quarter. Avanza Fonder AB raised its position in shares of Disc Medicine by 14.1% during the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company's stock worth $151,000 after acquiring an additional 235 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in Disc Medicine by 15,137.5% during the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company's stock worth $161,000 after buying an additional 2,422 shares during the period. Institutional investors and hedge funds own 83.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Raymond James Financial reaffirmed a "market perform" rating on shares of Disc Medicine in a research report on Thursday, January 15th. Wedbush cut their price target on Disc Medicine from $110.00 to $88.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 17th. UBS Group reaffirmed an "overweight" rating on shares of Disc Medicine in a research report on Thursday, January 15th. Morgan Stanley set a $75.00 price target on Disc Medicine in a research report on Tuesday, February 17th. Finally, BMO Capital Markets cut their price target on Disc Medicine from $120.00 to $100.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $104.80.

Disc Medicine Trading Up 1.5%

IRON opened at $66.91 on Friday. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -11.17 and a beta of 0.93. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50. The business's 50 day moving average is $64.79 and its two-hundred day moving average is $76.14. The company has a quick ratio of 21.94, a current ratio of 21.94 and a debt-to-equity ratio of 0.04.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.69) by $0.07. The company had revenue of ($19.88) million during the quarter, compared to analyst estimates of $0.15 million. On average, research analysts predict that Disc Medicine, Inc. will post -6.68 EPS for the current year.

Insiders Place Their Bets

In other news, COO Jonathan Yen-Wen Yu sold 3,231 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total value of $203,100.66. Following the transaction, the chief operating officer owned 54,324 shares of the company's stock, valued at approximately $3,414,806.64. The trade was a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Pamela Stephenson sold 5,531 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $347,678.66. Following the completion of the transaction, the insider directly owned 80,998 shares in the company, valued at approximately $5,091,534.28. The trade was a 6.39% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 59,410 shares of company stock valued at $3,840,013. 3.64% of the stock is owned by company insiders.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.